Work

RAS pathway biomarkers for breast cancer prognosis.

Year: 2016

Type: article

Abstract: Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer with poor prognosis. The prognostic RAS pathway biomarkers can be used to identify resistant tumour clones, stratify patients and guide therapies.

Source: PubMed

Authors: Lauren L Siewertsz van Reesema, Michael P Lee, Vasilena Zheleva, Janet S Winston, Caroline F O'Connor, Roger R Perry, Richard A Hoefer, Amy H Tang

Institutions: Eastern Virginia Medical School, Sentara Norfolk General Hospital, Sentara CarePlex Hospital

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Cancer Institute, National Institute of General Medical Sciences

Awards: Regulated Proteolysis in RAS Signal Transduction, SIAH2-Dependent Proteolysis in Cell Migration, Tumor Growth and Cancer Metastasis

OpenAlex ID: W2998022940

FWCI: 0.471

Cites: 51

Cited by: 14

Related to: 10